Get started
Author

Jieling Miao

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
2020 · Mary W Redman, Vassiliki A Papadimitrakopoulou, et al. · The Lancet Oncology · 125
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial
2023 · Eve Rodler, Priyanka Sharma, et al. · The Lancet Oncology · 99
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
2019 · Charu Aggarwal, Mary W. Redman, et al. · Journal of Thoracic Oncology · 89
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
2021 · Kevin Kalinsky, William E Barlow, et al. · Cancer Research · 87
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
2019 · Corey J. Langer, Mary W. Redman, et al. · Journal of Thoracic Oncology · 85
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
2019 · Julie R Gralow, William E Barlow, et al. · JNCI Journal of the National Cancer Institute · 78
SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
2019 · Martin J. Edelman, Mary W. Redman, et al. · Journal of Thoracic Oncology · 76
PDF
Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study
2019 · Costanza Paoletti, Jieling Miao, et al. · Clinical Cancer Research · 72
PDF
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403
2020 · Sarah B. Goldberg, Mary W. Redman, et al. · Journal of Clinical Oncology · 65
PDF
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)
2022 · Philip C. Mack, Jieling Miao, et al. · Clinical Cancer Research · 57
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
2019 · Anne S. Tsao, Jieling Miao, et al. · Journal of Clinical Oncology · 52
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
2020 · Priyanka Sharma, Eve Rodler, et al. · Journal of Clinical Oncology · 49
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
2021 · Natasha B Leighl, Mary W Redman, et al. · Journal for ImmunoTherapy of Cancer · 48
PDF
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929
2024 · Nagla Abdel Karim, Jieling Miao, et al. · Journal of Thoracic Oncology · 43
PDF
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
2020 · Darya A. Kizub, Jieling Miao, et al. · Supportive Care in Cancer · 39
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
2023 · Nagla Fawzy Abdel Karim, Jieling Miao, et al. · Journal of Clinical Oncology · 34
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
2021 · Taofeek K. Owonikoko, Mary W. Redman, et al. · Clinical Lung Cancer · 31
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)
2021 · Athanassios Argiris, Jieling Miao, et al. · Clinical Lung Cancer · 29
PDF
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2023 · Shirish M. Gadgeel, Jieling Miao, et al. · Clinical Cancer Research · 21
PDF
SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.
2025 · Charles B. Simone, Megan Eileen Daly, et al. · Journal of Clinical Oncology · 20
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer
2023 · Afroditi Nanou, Jieling Miao, et al. · JCO Precision Oncology · 20
PDF
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
2024 · Mariana Chavez-MacGregor, Jieling Miao, et al. · Journal of Clinical Oncology · 17
PDF
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.
2017 · Charu Aggarwal, Mary Weber Redman, et al. · Journal of Clinical Oncology · 17
A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
2017 · James Lloyd Wade, Corey J. Langer, et al. · Journal of Clinical Oncology · 16
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
2019 · Shirish M. Gadgeel, Jieling Miao, et al. · Journal of Clinical Oncology · 15
Works count: 114
Citation count: 1,416
H-index: 20
I10-index: 31
Year
Topic
Type